Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

XEOMIN should be discontinued and appropriate medical therapy immediately instituted.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [See Boxed Warning]. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. These reactions can occur within hours to weeks after injection with botulinum toxin.
  • Cervical Dystonia: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm:  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory comp
    '/>"/>

  • SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
    (Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
    (Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
    Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
    ... Feb. 1, 2011 /PRNewswire-Asia-FirstCall/ --  China Medicine Corporation ... "Company"), a leading manufacturer, developer and distributor of ... health products in the People,s Republic of China, ... manufacturing license from the Chinese Ministry of Agriculture ...
    ... 2011 Stryker Corporation (NYSE: SYK ) ... of its OP-1 product family, which includes OP-1 Implant, ... bone applications. The transaction also includes the sale of ... Stryker is one of the world,s leading medical technology ...
    Cached Medicine Technology:China Medicine Corporation Receives Manufacturing License for rADTZ 2China Medicine Corporation Receives Manufacturing License for rADTZ 3
    (Date:7/24/2014)... shuts off nighttime production of the hormone melatonin, renders ... breast cancer drug, says a new study by Tulane ... and Melatonin Disruption by Exposure to Light at Night ... published in the journal Cancer Research , is ... the success of tamoxifen in treating breast cancer. , ...
    (Date:7/24/2014)... Ticket Down is a reliable source ... at the Sports Authority Field on July 26th. For the ... has brought some of the best club teams from around the ... still being raved about weeks after its completion, fans – new ... of the biggest stars in the world compete. Some of these ...
    (Date:7/24/2014)... 2014 Four Seasons Resort Maui ... its $3 million renovation of the famed Maile suite ... suites, just in time to welcome summer guests vacationing ... direction from the internationally-acclaimed BraytonHughes Design Studios, San Francisco ... property and the largest in Hawaii—received a complete re-envisioning. ...
    (Date:7/24/2014)... In a July 9th article in the Money ... Lotus Blossom Consulting LLC , was quoted in a Family ... Cut the High Cost of Infertility . Her advice began ... maximize your chance of success from the first attempt.” The ... “I am always happy to talk with the media ...
    (Date:7/24/2014)... (PRWEB) July 24, 2014 CarePoint ... specialist in hematology and oncology, Dr. Hitendra Upadhyaya, ... Our system welcomes Dr. Upadhyaya to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
    Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
    ... on Science, Not IdeologyWASHINGTON, March 23 Today, the ... York ruled that the Food and Drug Administration (FDA) ... dedicated emergency contraceptive product) based on age was "arbitrary ... faith decision-making." The court ordered the FDA to extend ...
    ... Recommended levels in foods need to be increased, experts ... the course of two decades, vitamin D levels have ... Low levels of vitamin D have been associated with ... adults. Recent research has also linked insufficient vitamin D ...
    ... seen with tightest control of risk factors, researchers report ... control of the major risk factors for heart disease ... a new study shows. , And so the current ... LDL cholesterol might need to be tightened even further, ...
    ... a Decision Based on Scientific Fact, Not PoliticsNEW YORK, March ... the Eastern District of New York rejected the Food and ... emergency contraceptive Plan B to women over 18, ruling that ... The court ordered the agency to reconsider its decision. ...
    ... in Virginia, West Virginia and Maryland to hold annual convention recognizing ... ... 23, 2009 -- 200 emergency and 911 professionals will gather in ... safety sector. The 16th Annual Tri-State Telecommunicators Banquet and Awards ...
    ... Inform Healthcare DecisionsPHILADELPHIA, March 23 ... when selecting a hospital for treatment, thanks to ... and facility.Synthesizing extensive data from the 2003-2007 ... Hospital Performance Reports (PHC4) into a searchable format, ...
    Cached Medicine News:Health News:Advocates for Youth Applauds Court Ruling on EC Age Restriction 2Health News:Many Americans Fall Short on Their Vitamin D 2Health News:Many Americans Fall Short on Their Vitamin D 3Health News:Many Americans Fall Short on Their Vitamin D 4Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 2Health News:Federal Court Rules FDA Must Reconsider Plan B Decision 3Health News:LLE to Sponsor 16th Annual Tri-State Telecommunicators Banquet and Awards Ceremony 2Health News:New Site Compares Pennsylvania Hospitals 2
    ... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
    ... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
    ... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
    Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
    Medicine Products: